JP2020504131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504131A5 JP2020504131A5 JP2019536488A JP2019536488A JP2020504131A5 JP 2020504131 A5 JP2020504131 A5 JP 2020504131A5 JP 2019536488 A JP2019536488 A JP 2019536488A JP 2019536488 A JP2019536488 A JP 2019536488A JP 2020504131 A5 JP2020504131 A5 JP 2020504131A5
- Authority
- JP
- Japan
- Prior art keywords
- galactosidase
- recombinant human
- weeks
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192939A JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442537P | 2017-01-05 | 2017-01-05 | |
| US62/442,537 | 2017-01-05 | ||
| PCT/IL2018/050018 WO2018127920A1 (en) | 2017-01-05 | 2018-01-05 | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192939A Division JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504131A JP2020504131A (ja) | 2020-02-06 |
| JP2020504131A5 true JP2020504131A5 (https=) | 2021-02-12 |
Family
ID=62790830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536488A Pending JP2020504131A (ja) | 2017-01-05 | 2018-01-05 | 安定化α−ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
| JP2022192939A Pending JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192939A Pending JP2023022244A (ja) | 2017-01-05 | 2022-12-01 | 安定化α－ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12194079B2 (https=) |
| EP (1) | EP3565583A4 (https=) |
| JP (2) | JP2020504131A (https=) |
| KR (2) | KR20190103320A (https=) |
| CN (2) | CN110381987A (https=) |
| AU (1) | AU2018205891B2 (https=) |
| BR (1) | BR112019013920A2 (https=) |
| CA (1) | CA3048151A1 (https=) |
| CL (1) | CL2019001867A1 (https=) |
| IL (1) | IL267863A (https=) |
| MX (1) | MX2019008076A (https=) |
| NZ (1) | NZ755725A (https=) |
| WO (1) | WO2018127920A1 (https=) |
| ZA (1) | ZA201904850B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| AR120055A1 (es) * | 2019-06-11 | 2022-02-02 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal |
| CN116419759A (zh) * | 2020-11-13 | 2023-07-11 | 韩美药品株式会社 | 治疗酶融合蛋白在预防和治疗由法布里病引起或伴有法布里病的神经病中的用途 |
| JP2023549323A (ja) * | 2020-11-13 | 2023-11-24 | ハンミ ファーマシューティカル カンパニー リミテッド | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| EP1503788B1 (en) * | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| EP1877099B1 (en) * | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2192924B1 (en) | 2007-08-20 | 2017-10-11 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| WO2011107990A1 (en) | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| WO2011061736A1 (en) | 2009-11-17 | 2011-05-26 | Protalix Ltd. | Alkaline alpha galactosidase for the treatment of fabry disease |
| CN103443270B (zh) * | 2011-01-20 | 2017-06-06 | 普罗塔里克斯有限公司 | 用于在植物和植物细胞中表达α‑半乳糖苷酶的核酸构建体 |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
-
2018
- 2018-01-05 EP EP18736643.0A patent/EP3565583A4/en active Pending
- 2018-01-05 WO PCT/IL2018/050018 patent/WO2018127920A1/en not_active Ceased
- 2018-01-05 BR BR112019013920A patent/BR112019013920A2/pt unknown
- 2018-01-05 KR KR1020197023039A patent/KR20190103320A/ko not_active Ceased
- 2018-01-05 KR KR1020247008410A patent/KR20240042110A/ko not_active Ceased
- 2018-01-05 CA CA3048151A patent/CA3048151A1/en active Pending
- 2018-01-05 AU AU2018205891A patent/AU2018205891B2/en active Active
- 2018-01-05 NZ NZ755725A patent/NZ755725A/en unknown
- 2018-01-05 CN CN201880016068.5A patent/CN110381987A/zh active Pending
- 2018-01-05 CN CN202410140178.XA patent/CN117959455A/zh active Pending
- 2018-01-05 US US16/476,084 patent/US12194079B2/en active Active
- 2018-01-05 JP JP2019536488A patent/JP2020504131A/ja active Pending
- 2018-01-05 MX MX2019008076A patent/MX2019008076A/es unknown
-
2019
- 2019-07-04 CL CL2019001867A patent/CL2019001867A1/es unknown
- 2019-07-04 IL IL267863A patent/IL267863A/en unknown
- 2019-07-24 ZA ZA2019/04850A patent/ZA201904850B/en unknown
-
2022
- 2022-12-01 JP JP2022192939A patent/JP2023022244A/ja active Pending
-
2025
- 2025-01-10 US US19/015,746 patent/US20250134968A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504131A5 (https=) | ||
| CN101111154B (zh) | 联合免疫基因疗法和化学疗法用于治疗癌症和过度增生性疾病 | |
| JP2017527532A5 (https=) | ||
| JP2014500295A5 (https=) | ||
| JP2021505661A5 (https=) | ||
| JP2021509916A5 (https=) | ||
| CA2522535A1 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
| JP2012525393A5 (https=) | ||
| US20100266590A1 (en) | Combination therapy | |
| JP2019131588A5 (ja) | 抗そう痒剤 | |
| JP2007520452A5 (https=) | ||
| EP1201247B1 (en) | Treatment of metastatic renal cell carcinoma | |
| JP2019524637A (ja) | 抗腫瘍薬物の効果を有する併用薬物 | |
| JP2021001184A (ja) | ペグ化インターフェロンのための投薬計画 | |
| JP2005512946A5 (https=) | ||
| JP2021535163A5 (https=) | ||
| JP2020531495A5 (https=) | ||
| WO2023272831A1 (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JPWO2023052363A5 (https=) | ||
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| CN104434908A (zh) | 山奈酚在抑制受体对器官移植排斥反应药物中的应用 | |
| US12053478B2 (en) | Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies | |
| JP6112009B2 (ja) | 体腔液貯留抑制剤 | |
| RU2019124280A (ru) | СХЕМА ЛЕЧЕНИЯ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ФАБРИ С ИСПОЛЬЗОВАНИЕМ СТАБИЛИЗИРОВАННОЙ α-ГАЛАКТОЗИДАЗЫ | |
| NZ768282A (en) | Compounds including a mutant kras sequence and a lipid and uses thereof |